ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 692

High Plasma Factor XIII Transglutaminase Activity Inversely Correlates with SLE Disease Activity Yet Associates with Higher Carotid Artery IMT and Low CD14+CD16+ Monocyte Levels

Brian Skaggs1, Isao Matsuura2, Elaine Lourenco1, Eloise Olmos3, Jennifer M. Grossman1 and Maureen A. McMahon1, 1University of California-Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, 2Department of Rheumatology, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan, 3Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biomarkers and systemic lupus erythematosus (SLE), Disease Activity

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Session Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The transglutaminase Factor XIII (FXIII) stabilizes blood clots through crosslinking fibrin lysine and glutamine residues at the end of the complement cascade. Enzymatic activity and plasma levels of FXIII appear to be tightly controlled, as excess FXIII can lead to increased arterial plaque, yet low or absent FXIII leads to thrombosis due to fibrin instability. In addition, recent data suggest that tissue macrophages could be the main source of plasma FXIII. Anti-FXIII antibodies have been observed in SLE and correlate with brain hemorrhage, although other clinical correlations between plasma FXIII and SLE remain unexplored.

Methods: 120 SLE patients were recruited from a pre-existing longitudinal cohort developed to study atherosclerosis in SLE. Anti-dsDNA, C3 and C4 levels were analyzed in the clinical lab of our university hospital. Carotid ultrasound was performed to determine the presence or absence of subclinical atherosclerosis and intima-media thickness (IMT). The Technochrom FXIII kit (Diapharma, West Chester, OH) was utilized to determine plasma FXIII transglutaminase activity. Plasma monocyte subpopulations were identified by flow cytometry using anti-CD14 and –CD16 fluorescent antibodies (Biolegend).

Results: 66/120 SLE patients had high plasma FXIII transglutaminase activity (>143% of the mean of the standard curve). SLEDAI was significantly lower in the high FXIII activity group compared to patients with normal FXIII activity (2.08±3.9 versus 4.2±3.1, p=0.006). In addition, anti-dsDNA antibody levels were significantly lower in the high FXIII activity group (87.5±255.7 versus 274.7±323.8, p=0.041). Significantly higher levels of plasma C3 and C4 levels were also observed in the high FXIII activity group. Taken together, these results show that higher FXIII activity might be a biomarker for lower SLE disease activity.

In contrast, percentages of CD14+CD16int and CD14+CD16hi plasma monocytes (considered precursors to anti-inflammatory ‘M2” macrophages) were inversely proportional to FXIII activity (r=-0.54, p=0.008; r=-.064, p=0.005, respectively), although there was no correlation between classical plasma monocyte levels (CD14+CD16–, ‘M1’ macrophage precursors) and FXIII enzymatic activity. In addition, IMT positively correlated with FXIII activity (r=0.40, p=0.01). No correlations between carotid plaque presence and FXIII activity were noted.

Conclusion: High plasma FXIII transglutaminase activity correlates with multiple measures of low disease activity in SLE patients. Conversely, high FXIII activity inversely correlated with low numbers of anti-inflammatory monocytes. Higher IMT was also observed in patients with high FXIII activity. Careful regulation of FXIII enzymatic activity, and, by extension, its crucial role in fibrin crosslinking and plaque stabilization, could be dysregulated in a subset of SLE patients at risk for accelerated atherosclerosis.


Disclosure: B. Skaggs, None; I. Matsuura, None; E. Lourenco, None; E. Olmos, None; J. M. Grossman, Medimmune, 2,AstraZeneca, 2,Aurinia, 2,Genentech and Biogen IDEC Inc., 2; M. A. McMahon, None.

To cite this abstract in AMA style:

Skaggs B, Matsuura I, Lourenco E, Olmos E, Grossman JM, McMahon MA. High Plasma Factor XIII Transglutaminase Activity Inversely Correlates with SLE Disease Activity Yet Associates with Higher Carotid Artery IMT and Low CD14+CD16+ Monocyte Levels [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/high-plasma-factor-xiii-transglutaminase-activity-inversely-correlates-with-sle-disease-activity-yet-associates-with-higher-carotid-artery-imt-and-low-cd14cd16-monocyte-levels/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-plasma-factor-xiii-transglutaminase-activity-inversely-correlates-with-sle-disease-activity-yet-associates-with-higher-carotid-artery-imt-and-low-cd14cd16-monocyte-levels/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences